cGAS-STING: From immunology and oncology view.
10.1097/CM9.0000000000003889
- Author:
Xiangxiang LIU
1
;
Chengshi DING
1
;
Jun LU
2
;
Na ZHANG
3
Author Information
1. College of Life Science, Zaozhuang University, Zaozhuang, Shandong 277160, China.
2. The Institute of Genetics and Cytology, Northeast Normal University, Changchun, Jilin 130024, China.
3. School of Life Sciences, Jilin University, Changchun, Jilin 130012, China.
- Publication Type:Review
- Keywords:
Autoimmune disorders;
Cancer immunotherapy;
Targeted therapies;
Type I interferons;
cGAS–STING pathway
- MeSH:
Humans;
Nucleotidyltransferases/metabolism*;
Membrane Proteins/metabolism*;
Animals;
Immunity, Innate/physiology*;
Signal Transduction/physiology*;
Neoplasms/metabolism*
- From:
Chinese Medical Journal
2025;138(23):3050-3068
- CountryChina
- Language:English
-
Abstract:
The cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes (cGAS-STING) pathway is a cornerstone of host innate immunity, playing a central role in detecting cytosolic double-stranded DNA of both endogenous and exogenous origins. Upon activation, cGAS synthesizes the second messenger 2'3'-cyclic GMP-AMP (cGAMP), which binds and activates STING to trigger downstream immune responses, including the production of type I interferons and proinflammatory cytokines. Emerging studies highlight the cGAS-STING pathway as a promising therapeutic target for preventing and treating diverse pathologies, with particularly transformative potential in anticancer therapies. In this review, we dissect the key findings, functions, and associated components of the cGAS-STING pathway. In addition, we emphasize the factors that upregulate or downregulate the pathway, as well as the role of the cGAS-STING pathway in health and disease. By integrating mechanistic insights with clinical perspectives, this review aims to bridge fundamental discoveries with therapeutic applications of cGAS-STING biology.
